possibilities for gene therapy with the altered virus in cystic fibrosis. In particular, 
information regarding the amount of virus needed and the effects of the virus on the cells 
of the airway will be critical for further studies which might involve giving the virus to 
the bronchial airways of the lung to treat the disease. 
4. ALTERNATIVES THAT ARE AVAILABLE TO YOU : 
You may elect not to participate in this study and this decision will not affect your care at 
the University of Iowa. Treatments of cystic fibrosis include: chest physiotherapy, 
antibiotics, nutritional and dietary measures, and experimental agents which might reduce 
the thickness of the mucus. These treatments will also be available to you during and 
after the study. Since this study will not directly treat your lungs, a decision not to 
participate will not affect your health. 
5. CONFIDENTIALITY : 
A record of your participation in this research will be maintained, but this record will be 
kept confidential. You will be assigned a study number and information will be kept 
under the number rather than your name. All requests for information will be directed to 
the University of Iowa Health Science Relations Office to minimize the risk that your 
identity will be disclosed to the public. Gene therapy is very interesting to the general 
public. Although every effort will be made to maintain your privacy, it is possible that 
the news media or other individuals might learn your identify and spread this 
information, even if you do not want this to happen. 
6. m5OJ0SIJE E ..Q F I NF OR M ATIO N T Q REGULATORY AG E NCIES: 
The U.S. Food and Drug Administration (FDA), National Institutes of Health, and 
Genzyme Corporation may inspect and copy your medical records relating to this study, 
and the results of the study will be reported to the sponsor, the FDA and perhaps to other 
regulatory agencies. This information will be treated confidentially and, in the event of 
any publication regarding this study, your identity will not be disclosed. 
7. RIGHT TO ASK QUESTIONS : 
Questions about this research will be answered by either Dr. Michael J. Welsh, M.D., 
University of Iowa Medical Center, telephone (319) 335-7619 or Dr. Joseph Zabner, 
MD., University of Iowa Medical Center, telephone (319) 335-7574. 
8. RIGHT TO WITHDRAW : 
Your participation in this study is voluntary. No penalty or loss of benefits to which you 
are entitled will occur if you decide not to participate. After enrollment in the study, you 
may discontinue participation at any time before application of the virus without penalty. 
Because you will receive a virus for which safety data in humans is not yet available, the 
risks are not yet fully defined. Therefore, if after having received the virus, you wish to 
withdraw from the study, you may do so but we request that you continue to return to the 
clinic for evaluation. If you feel that you are not able to make this commitment, we 
recommend that you not enter the study. 
[ 894 ] 
Recombinant DNA Research, Volume 18 
